Bioprocessing reagent market projected to top $16 billion by 2030

The Business Research Company says the global bioprocessing reagent market will grow from $9.03 billion in 2025 to $10.11 billion in 2026, then reach $16.06 billion by 2030. The outlook is being driven by rising demand for biologics, monoclonal antibodies, cell and gene therapy production, and more automated biomanufacturing.

Why it matters: - The bioprocessing reagent market supports biologics manufacturing, cell culture, purification and downstream processing across pharmaceutical and biotech production. - Rising demand for monoclonal antibodies, biosimilars and advanced biologics is increasing the need for specialized reagents and scalable manufacturing workflows. - The market outlook points to faster adoption of automation, continuous processing and single-use systems as biomanufacturers seek higher efficiency and lower contamination risk.

What happened: - The Business Research Company released a market outlook on the bioprocessing reagent market on June 30, 2026. - The report estimates the market will grow from $9.03 billion in 2025 to $10.11 billion in 2026. - The report projects the market will reach $16.06 billion by 2030. - North America was the largest regional market in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The company also offered a free sample of the report and the full market report.

The details: - Bioprocessing reagents include media components, buffers, enzymes and purification agents. - These materials help support cell growth, protein expression and downstream processing. - The report links recent growth to wider use of cell culture methods in biologics manufacturing. - The report also cites higher monoclonal antibody production, stronger pharmaceutical and biotech research infrastructure, vaccine demand and early industrial fermentation use. - Looking ahead, the report expects growth to be supported by biosimilars, advanced biologics, automated and continuous bioprocessing, cell and gene therapy investment, personalized medicine and cost-efficient biomanufacturing. - The report identifies AI-driven bioprocess optimization, single-use systems, continuous processing, new chromatography resins and sustainable bio-based reagents as key trends. - The report says 21 antibody therapeutics received initial approvals in 2024, up from 16 in 2023, citing National Center for Biotechnology Information data from December 2024.

Between the lines: - The market forecast reflects a broader shift in drug development toward complex biologic therapies that require more controlled and specialized production inputs. - The emphasis on sustainability and automation suggests reagent suppliers are competing not just on performance, but also on manufacturing efficiency and environmental profile. - The regional split points to an established North American base and a faster-expanding Asia-Pacific manufacturing footprint.

What's next: - The Business Research Company expects demand to keep rising as biologics, biosimilars and cell and gene therapies move deeper into commercial production. - Continued investment in automated and continuous systems is likely to reshape reagent requirements across large-scale manufacturing sites. - Suppliers focused on high-purity, scalable and bio-based products may be best positioned as the market expands.

The bottom line: - Bioprocessing reagents are moving from a supporting input to a strategic enabler of the next wave of biologic drug manufacturing.